Polycystic ovary syndrome (PCOS) is a hormonal endocrine disorder which affects women of age 15 to 49 years. This disease which leads to formation of lumps on ovaries creating insufficiency of ovulation hormone in female. PCOS can also cause missed or irregular menstrual periods and an irregular periods that can lead to infertility and development of cysts in ovaries.
Based on drug class, polycystic
ovarian syndrome treatment market is segmented into insulin sensitizing agent,
antiandrogens, oral contraceptive, anti-obesity drugs, and others. Insulin
sensitizing agent segment dominates the market owing to significant adoption of
insulin sensitizing agents over the first line treatment for managing PCOS.
Based on surgery type, market is segmented into laparoscopic ovarian drilling
and ovarian wedge resection. In addition, based on distribution channel, market
is segmented into drug stores & retail pharmacies, hospital pharmacies, and
online providers. The online providers segment is projected to exhibit
significant growth due to increase in awareness of online providers, growth in
preference for online purchasing of drugs over the traditional methods, and
rise in number of internet users during the forecast period.
The polycystic ovarian syndrome
treatment market is driven by increase in prevalence of PCOS, followed by surge
in popularity of combination therapy, rise in awareness among the patient
population about PCOS, growth in technological advancements for detection of
PCOS, rise in demand for PCOS medication, and easy accessibility to PCOS
therapeutics. However, unknown etiology & pathophysiology of PCOS and lack
of approved therapeutics may impact the market. Moreover, higher number of
unmet needs for treatment of PCOS is a key opportunity for market.
Based on geography, the
North-American is a leading region in global polycystic ovarian syndrome
treatment market owing to presence of multiple local and global
biopharmaceutical companies in the region. Whereas, the Asian-Pacific and
European regions are estimated to exhibit substantial growth rate due to rise
in adoption of polycystic ovarian syndrome treatment products over the forecast
period. In upcoming years, it is expected that future of the market will be
optimistic caused by growth in awareness about polycystic ovarian syndrome
treatment coupled with rise in healthcare reforms during the forecast period.
The global polycystic ovarian syndrome treatment market was valued at US $2,902
million in 2018, and is projected to reach US $4,184 million by 2026,
registering a CAGR of 4.7% from 2019-2026.
For More Information, Click on the Link Below:-
Global
Polycystic Ovarian Syndrome Treatment Market
Contact Us:-
Ken
Research
Ankur Gupta, Head Marketing &
Communications
No comments:
Post a Comment